In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:

• How to sequence currently available therapies after relapse
• Challenges with using BCMA-targeted agents in clinical practice
• Experts’ thoughts on the potential approval of bispecific agents

Presenters include:

Paul G. Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts

Natalie S. Callander, MD
Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director
Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3Fc7eMK